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Abstract
TRPM8 (Transient Receptor Potential Melastatin-8) is a cold- and menthol-gated ion channel necessary for the detection of
cold temperatures in the mammalian peripheral nervous system. Functioning TRPM8 channels are required for behavioral
responses to innocuous cool, noxious cold, injury-evoked cold hypersensitivity, cooling-mediated analgesia, and
thermoregulation. Because of these various roles, the ability to pharmacologically manipulate TRPM8 function to alter
the excitability of cold-sensing neurons may have broad impact clinically. Here we examined a novel compound, PBMC (1-
phenylethyl-4-(benzyloxy)-3-methoxybenzyl(2-aminoethyl)carbamate) which robustly and selectively inhibited TRPM8
channels in vitro with sub-nanomolar affinity, as determined by calcium microfluorimetry and electrophysiology. The
actions of PBMC were selective for TRPM8, with no functional effects observed for the sensory ion channels TRPV1 and
TRPA1. PBMC altered TRPM8 gating by shifting the voltage-dependence of menthol-evoked currents towards positive
membrane potentials. When administered systemically to mice, PBMC treatment produced a dose-dependent hypothermia
in wildtype animals while TRPM8-knockout mice remained unaffected. This hypothermic response was reduced at lower
doses, whereas responses to evaporative cooling were still significantly attenuated. Lastly, systemic PBMC also diminished
cold hypersensitivity in inflammatory and nerve-injury pain models, but was ineffective against oxaliplatin-induced
neuropathic cold hypersensitivity, despite our findings that TRPM8 is required for the cold-related symptoms of this
pathology. Thus PBMC is an attractive compound that serves as a template for the formulation of highly specific and potent
TRPM8 antagonists that will have utility both in vitro and in vivo.
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Introduction
The cold and menthol-gated ion channel TRPM8 [1,2] serves as
a neuronal sensor ofcold temperatures and is essential forinnocuous
cool and noxious cold sensations [3,4,5,6,7]. Mice lacking functional
TRPM8 channels are unable to discriminate between mildly warm
and mildly cool temperatures, and do not show normal aversion to
temperatures in the noxious cold range [6]. Moreover, recent
evidence suggests that the channel is necessary for increased cold
sensitivity associated with injury [4,8,9]. Somewhat paradoxically,
the channel is also required for the analgesia (pain relief) associated
with mild cooling and cooling compounds [5,10]. Additionally,
TRPM8 has recently been reported to be involved in thermoreg-
ulation [11], a role that is not entirely unexpected given that other
temperature sensitive ion channels, particularly the heat-gated
TRPV1, have also been implicated in regulating body temperature
[12]. For example, several studies have shown that TRPV1-null
mice display attenuated fever responses, and TRPV1 antagonism
induces thermogenesis in rats and humans [12,13,14,15].
Because TRPM8 is involved in a broad and diverse range of
physiological processes, particularly those relevant to human
health and disease, pharmaceuticals that manipulate channel
function are needed both as tools for further study of the channel,
and as potential therapeutic compounds [16]. With regard to
agonists, at least eighteen natural and synthetic compounds have
been found to activate the channel, including menthol, icilin, and
eucalyptol [1,2,16]. While many agonists have been described,
there are few channel antagonists reported in the literature, and
none that are selective for TRPM8 [16]. Of those reported, many
also act on other somatosensory-related ion channels, such as
TRPV1 and the irritant receptor TRPA1, suggesting a conserved
mechanism amongst these channels [17,18,19]. Capsazepine, a
well-known TRPV1 antagonist, also has non-specific activity on
voltage-gated calcium channels, nicotinic acetylcholine receptors,
and TRPM8 [20,21,22,23,24]. Similarly, while BCTC inhibits
TRPM8-mediated Ca
2+ influx, [24], this compound also functions
as a TRPA1 agonist [25]. Likewise, the anti-fungal medication
clotrimazole has strong TRPM8 antagonistic activity, but also
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25894robustly activates TRPV1 and TRPA1, actions consistent with the
commonly reported side effects of irritation and burning [26].
SKF96365, a non-specific blocker of several types of calcium
channels, receptor-operated channels, and inwardly rectifying
potassium channels [27,28], also inhibits TRPM8 in vitro [29].
Certain tryptamine derivatives that are ligands for 5-benzyloxy-
tryptamine receptors also act as TRPM8 antagonists [30]. Lastly,
ethanol, at concentrations of 1–3%, inhibits TRPM8 channel
function by disrupting interactions with the membrane phospho-
lipid phosphatidylinositol-4,5-bisphosphate (PIP2) [17,31], an
obligate molecule for TRPM8 channel function [32,33]. Together,
these chemicals present a range of pharmacological tools to
regulate TRPM8 function, yet each of these compounds has off-
target effects, thus complicating their utility in the investigation of
the role of TRPM8 as a drug target.
The goal of this study was to determine the selectivity and
potency of a candidate TRPM8 antagonist 1-phenylethyl-4-
(benzyloxy)-3-methoxybenzyl(2-aminoethyl)carbamate (Figure 1;
abbreviated PBMC) in inhibiting TRPM8 at the levels of in vitro
channel function and in vivo behavior under both normal and
pathological conditions. Our results show that PBMC is a suitable
structural template for formulations of specific and highly potent
TRPM8 antagonists. Moreover, blockade of TRPM8 disrupted
thermoregulation and normal thermosensation as well as attenu-
ated injury-evoked painful cold hypersensitivity, further establish-
ing a role for TRPM8 in these physiological processes.
Results
PBMC selectively blocks TRPM8 activity
We first tested the effects of PBMC on menthol-induced
responses in heterologous cells expressing TRPM8 channels using
calcium microfluorimetry [32]. In HEK293T cells transiently
transfected with the mouse orthologue of TRPM8 (mTRPM8),
brief and repeated exposure to 200 mM menthol evoked a robust
increase in intracellular calcium, measured as a change in the
Fura-2 fluorescence signal ratio (Figure 2A,B). Calcium levels
returned to baseline over the course of ten minutes, and due to
channel adaptation [32], the second menthol response was
reduced in these assays, but still robustly increased intracellular
Ca
2+. To test the ability of the candidate compound to block
TRPM8 activation, we perfused PBMC (25 nM) or vehicle
between the first and second applications of menthol, observing
complete abolishment of menthol-evoked Ca
2+ responses at this
concentration (Figure 2A,C). Data from several independent
experiments showed that the average second response was
65.062.0% of the first response when vehicle was applied to the
bath, compared to 7.061.0% with 25 nM PBMC (Figure 3C;
n=124 cells for vehicle, n=108 cells for PBMC; Student’s t-test,
p,0.001).
Next we determined whether PBMC blocks TRPM8 activity in
native cells. Mouse trigeminal ganglion (TG) neurons were
enzymatically dispersed as described [32], and changes in
intracellular Ca
2+ were monitored as previously. Transient
addition of 200 mM menthol evoked a robust increase in the
Fura-2 ratio in a small fraction of cells (Figure 3A; arrow), whereas
responses to a second application were abolished by preincubation
with PBMC (Figure 3A,B; 50 nM). Of note, PBMC alone did not
produce any change in intracellular Ca
2+, nor did it prevent
depolarization-induced Ca
2+ increases evoked by addition of
50 mM KCl to the perfusate. These results show that PBMC also
blocks TRPM8 activity in native cells and has no appreciable
effects on intracellular Ca
2+ transients evoked by K
+-induced
depolarization.
As stated above, all known TRPM8 antagonists have effects on
other ionic mechanisms, as either antagonists or agonists,
including the somatosensory-relevant channels TRPV1 and
TRPA1. Thus, to further test the selectivity of PBMC for TRPM8,
we performed similar calcium imaging experiments with heterol-
ogous cells expressing TRPV1 or TRPA1. Cells transfected with
rTRPV1 were subjected to two challenges with the TRPV1-
specific agonist capsaicin (1 mM), separated by incubation with
either vehicle or PBMC (25 nM). The averaged second responses
were 34.068.0% for vehicle and 25.0611.0% for PBMC
(Figure 3C; n=84 cells for vehicle, n=84 cells for PBMC;
Student’s t-test, p.0.05). Similarly, when cells transfected with
rTRPA1 were challenged twice with 10 mM allyl isothiocyanate
(AITC), the averaged second responses were 77.066.0% for
vehicle and 88.066.0% for PBMC (25 nM; Figure 3C; n=187
cells for vehicle, n=87 cells for PBMC; Student’s t-test, p.0.05).
Furthermore, we did not find any evidence of PBMC acting as an
agonist for these channels (not shown). Thus, PBMC shows
selective inhibition of heterologously expressed TRPM8 over
TRPV1 and TRPA1.
Next, we tested whether PBMC also attenuated cold-induced
TRPM8 activity, again using calcium microfluorimetry. In
HEK293T cells transiently transfected with mTRPM8, cooling
of the bath solution (from ,24 to 18uC) evoked a robust and
reproducible increase in intracellular calcium that returned to
baseline after the bath solution returned to room temperature
(Figure 4A,B), similar to what we have reported previously [32].
Consecutive cooling ramps separated by a five-minute incubation
with vehicle elicited calcium responses of similar magnitudes, with
the second response averaging to 82.061.0% of the first cold
challenge (Figure 4A,B,D; n=70 cells). However, when 25 nM
PBMC was applied between the cooling ramps, the second
calcium response was negligible at a value of 1.061.0% of the first
response (Figure 4A, C, D; n=65 cells; Student’s t-test, p,0.001
vehicle vs. PBMC). We therefore conclude that PBMC inhibits
both chemical and thermal activation of TRPM8.
PBMC inhibits TRPM8 channels in a dose-dependent
manner
To further characterize the effect of PBMC on TRPM8
function, we turned to whole-cell voltage clamp recordings as a
more direct method of observing the drug’s actions on TRPM8
channels. In heterologous cells, we recorded menthol-evoked
Figure 1. Structure of PBMC. 1-phenylethyl-4-(benzyloxy)-3-meth-
oxybenzyl(2-aminoethyl)carbamate.
doi:10.1371/journal.pone.0025894.g001
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2+ free external
solutions and 10 mM EGTA in the pipette) in order to exclude
calcium-mediated adaption from our analysis [32,33]. Under these
experimental conditions, menthol-evoked TRPM8 currents are
remarkably stable and show little to no rundown [1,32,33]. At
both positive (+80 mV) and negative (280 mV) membrane
potentials, a saturating concentration of menthol (500 mM) evoked
robust currents with strong outward rectification (Figure 5A,B).
These responses were significantly reduced by PBMC at
concentrations as low as 0.25 nM (Figure 5A), with nearly
complete functional block of channel activity at 2.5 nM
(Figure 5A,B). Dose-response relationships were performed and
by fitting the data with a sigmoidal Hill equation we observed an
IC50 of 0.6 nM at +80 mV and 0.4 nM at 280 mV (Figure 4C).
The Hill coefficient, n, was measured to be 1.1 and 1.4 at +80 mV
and 280 mV, respectively, suggesting a single binding site. This
makes PBMC the most potent TRPM8 antagonist reported to
date [16]. Moreover, the effects of PBMC were irreversible with
no recovery of menthol-evoked currents even after a twenty
minute washout (data not shown).
PBMC shifts the voltage-dependence of TRPM8 channels
TRPM8 gating is weakly voltage-dependent in that agonists such
as menthol and cold shift channel activation properties towards
more negative membrane potentials, thereby facilitating channel
opening at physiological voltages [34,35]. Previously we found that
calcium- and PIP2-dependent adaptation also correlates with a shift
in TRPM8 voltage-dependence, but towards more positive
membrane voltages, thereby reducing channel gating [32].
Therefore we asked whether PBMC’s effects on menthol-evoked
TRPM8 conductances produce a similar shift in the voltage
dependence of the channel. In heterologous cells expressing
mTRPM8, steady-state menthol-evoked currents were recorded at
23uC during voltage steps (2100 to +200 mV) from a holding
potential of 0 mV under basal conditions, in the presence of 1 mM
menthol, or with 1 mM menthol and a near-IC50 concentration of
PBMC (0.5 nM; Figure 6A). Normalized TRPM8 conductances for
each cell, referred to as G/Gmax, were plotted for the given voltages
under the three experimental conditions. We found that application
of menthol alone shifted the activation curve towards negative
membrane potentials, as reported previously [32,34,35]. However,
in the presence of PBMC, the menthol-induced normalized
conductance shifted back towards the basal state and more positive
membrane potentials (Figure 6B). The conductance-to-voltage
relationship was fitted with a Boltzmann function and we calculated
the half-maximal activation voltage (V1/2) under each condition.
The average basal (23uC) V1/2 was 218.2618.2 mV, with the
addition of menthol shifting this value to 79.1621.1 mV
(Figure 6C), data consistent with previous reports [32,34]. When
0.5 nM PBMC was added to the bath with menthol, this shifted the
average V1/2 to 171.2616.0 mV (Student’s t-test, p,0.01 menthol
vs menthol + PBMC). These results suggest that PBMC antagonizes
TRPM8 activity by shifting the voltage-dependence of channel
gating toward more positive voltages, thereby partially reversing the
effects of agonist activation.
PBMC affects body temperature in a dose-dependent
manner
Our in vitro data show that PBMC is a profoundly potent
TRPM8 antagonist with sub-nanomolar affinity. Therefore we
next determined if this compound is equally effective in blocking
channel function in vivo. It has been previously reported that TRP
channel antagonists can affect thermoregulatory processes, most
Figure 2. PBMC inhibits menthol-evoked TRPM8 responses. A) Representative images of HEK293T cells expressing mTRPM8. Pseudocolored
images of the 340/380 nm (excitation) Fura-2 ratio (R340/380) show low basal Ca
2+ before application of 200 mM menthol, which evoked a robust
increase in intracellular Ca
2+. A second application of menthol resulted in a second increase in intracellular Ca
2+ after a ten minute treatment with
vehicle (top row) but not after treatment with 25 nM PBMC (bottom row). B) Average changes in the Fura-2 ratio of vehicle-washed menthol-
responding cells show that the second menthol pulse resulted in a robust calcium influx, albeit to a smaller degree than that of the first pulse. C)
Average changes in the Fura-2 ratio of cells perfused with PBMC show that the drug abolished the second calcium increase.
doi:10.1371/journal.pone.0025894.g002
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antagonism [13]. Similarly, the potent TRPM8 agonist icilin is
well known to produce an intense behavioral response in rodents
that is manifested as shivering, ‘‘wet-dog’’ shaking and also results
in an increase in core body temperature in rats [11,36,37]. To
date, all known in vivo effects of icilin are dependent on TRPM8
[5,6], yet genetic evidence demonstrating that icilin-induced
hyperthermia is TRPM8-dependent is yet to be established.
Therefore, we first examined the role of TRPM8 activation in
thermoregulatory responses by subcutaneously injecting 10 mg/kg
icilin into wildtype and TRPM8-knockout mice (TRPM8
-/-)
implanted with thermal telemeters [3,6]. Consistent with data in
rats [36], we observed a pronounced hyperthermic effect of 1.6uC
on average in wildtype mice, which resolved within 90 minutes
(Figure 7A; n=4). However, this hyperthermic response was
absent in TRPM8
-/- mice, with only a small injection-related
artifact observed that was similar to vehicle injections (Figure 7A,
C; n=4). When we administered 1 mg/kg capsaicin s.c. to
wildtype and TRPM8
-/- mice we found a profound and transient
hypothermic effect of around 4uC that was similar in both
genotypes, indicating that the TRPM8
-/- mice were still able to
mountachemically-inducedthermoregulatoryresponse(Figure7B).
Injection of the DMSO/saline (DS) vehicle s.c. induced only a brief
increase in body temperature of around 0.5uC which peaked
within30 minutes post-injection inbothgenotypes(Figure 7C;n=4
each genotype).
We next determined if PBMC antagonism of TRPM8 alters
thermoregulatory responses in a likewise, yet reversed, manner.
However, we found that subcutaneous injections of the required
vehicle for PBMC (10% Solutol/20%PEG-200/saline (SPS))
resulted in intense grooming and scratching at the site of injection
in both wildtype and TRPM8
-/- mice. Since stress is known to
influence thermoregulation [38], we therefore switched to
intraperitoneal injections of solutions warmed to 37uC immedi-
ately before injection and administered as far away from the
telemeter implantation site as possible. This approach resulted in
no obvious adverse effects associated with intraperitoneal vehicle
injections (Figure 7D). Next, we tested a range of PBMC doses (2,
10, 20 mg/kg), finding no effect with 2 mg/kg (identical to vehicle,
data not shown) and a small, but significant drop in core body
Figure 3. PBMC shows selectivity for TRPM8. A) Representative pseudocolor images (n=4) of the Fura-2 ratio in cultured TG neurons. In this
field a single cell is robustly activated by 200 mM menthol (arrow), but after treatment with PBMC (50 nM) a subsequent menthol application was
ineffective. B) Ratio values of the cells shown in A (black trace: arrow; blue trace: arrowhead). Note that PBMC alone did not alter intracellular Ca
2+ in
menthol-insensitive, K
+-sensitive neurons (arrowhead). C) Average peak ratio values of the second menthol response presented as a percentage of
the first response compared for vehicle- (black bars; 65.062.0) and PBMC- (grey bars; 7.061.0) treated cells. 25 nM PBMC significantly inhibited
menthol responses in HEK293T cells transfected with TRPM8 as compared with vehicle controls (Student’s t-test, ***p,0.001). However, the drug did
not affect capsaicin responses in TRPV1-transfected cells or AITC responses in TRPA1-transfected cells (Student’s t-test, n.s. p.0.05).
doi:10.1371/journal.pone.0025894.g003
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by two hours post-injection (Figure 7E; n=4; p,0.05). Strikingly,
at 20 mg/kg, we observed a dramatic and severe hypothermic
effect of more than 6uC, with a drop in core body temperature to
below 30uC in one instance (Figure 7F; n=4). The drop in core
body temperature of more than two degrees lasted at least four
hours on average. Importantly, TRPM8
-/- mice showed no
fluctuations in core temperature besides the transient injection
artifact at all doses (n=4 each dose). These data show that
blockade of TRPM8 activity at high PBMC doses significantly
alters thermoregulation, providing pharmacological evidence that,
like TRPV1 [12], TRPM8 is involved in the maintenance of core
body temperature.
PBMC affects acute cold thermosensation
We and others have previously reported that TRPM8 is
required for behavioral responses to cooling over a broad range of
cold temperatures [3,4,5,6]. To test whether pharmacological
blockade of TRPM8 channels by PBMC affects normal thermo-
sensation, we gave mice intraperitoneal injections of 10 or 20 mg/
kg PBMC and assayed cold thermosensation at one hour post-
injection using the evaporative cooling assay [3,4]. When acetone
is applied to the mouse’s hindpaw, behavioral responses can be
scored according to the magnitude of the response [4]. Here, the
scores range from zero to five, with a zero score indicating no
response and a five the most severe response, which we observed
to be prolonged guarding of the hindpaw. When wildtype mice
Figure 4. PBMC inhibits cold-evoked TRPM8 responses. A) Representative images of HEK293T cells expressing mTRPM8. Pseudocolored
images of the 340/380 nm Fura-2 ratio (R340/380) show low basal Ca
2+ before cooling the bath solution, which evoked a robust increase in intracellular
Ca
2+. After treating the cells for five minutes with vehicle (top row) or 25 nM PBMC (bottom row), cells again displayed low basal Ca
2+ levels. A second
cooling of the bath resulted in a calcium increase in vehicle, but not PBMC-treated cells. B) Average changes in the R340/380 of vehicle-washed cold-
responding cells show that, under these conditions, the second cold pulse resulted in a robust influx of calcium into the intracellular space which was
only slightly smaller than that seen for the first cold pulse. C) Average changes in the R340/380 of cells washed with PBMC show that the drug
abolished the second calcium influx. D) 25 nM PBMC significantly inhibited cold responses in HEK293T cells transfected with TRPM8 as compared
with vehicle controls. Data are presented as the average value of the second response as a percentage of the first compared for vehicle- (black bars;
82.061.0) and PBMC- (grey bars; 0.460.4) treated cells (Student’s t-test, ***p,0.001).
doi:10.1371/journal.pone.0025894.g004
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paws was 2.260.1 (Figure 8A; n=9 mice). However, when these
animals were given 10 or 20 mg/kg PBMC, their scores decreased
to 1.860.1 or 1.460.1, respectively, with every mouse given the
lower dose exhibiting a decrease in response score (Figure 8A,B;
Student’s t-test vs. baseline, p,0.01 for 10 mg/kg and p,0.001
for 20 mg/kg). As the higher PBMC concentration lead to a
significant drop in core body temperature during the test period
(Figure 7F), we cannot exclude the possibility that the observed
behaviors are affected by the hypothermia associated with this
dose. Nonetheless, there were significantly reduced cold behaviors
with 10 mg/kg PBMC, a dose that did not produce a change in
core temperature beyond that observed with circadian rhythms
(35.3–38.0uC; Figure 7E and data not shown), suggesting that the
drug altered acute cold sensation.
PBMC attenuates injury-induced cold hypersensitivity
In addition to acute cold sensitivity, TRPM8 has also been
reported to be necessary for cold hypersensitivity in both
inflammatory and neuropathic pain models [4,9]. Therefore, we
next sought to determine if PBMC could alleviate these symptoms
in wildtype animals. First, to confirm that TRPM8 is indeed
required for inflammatory cold hypersensitivity we used unilateral
intraplantar injections of complete Freund’s adjuvant (CFA) into
the hindpaws of wildtype and TRPM8
-/- mice. When CFA was
injected into one hindpaw in wildtype mice, the acetone response
scores for that paw increased from 2.260.3 before the injection to
a peak of 3.560.3 by two days post-injury (Figure 9A; n=8;
ANOVA, p,0.05). No changes were observed in the un-injected
contralateral paw (not shown). However, in TRPM8
-/- mice, CFA
injection did not significantly change these responses beyond the
reduced behaviors we already observed in TRPM8
-/- animals at
baseline (Figure 9A; 1.960.4; n=8; ANOVA, p.0.05). These
data reaffirm the previous report that CFA-induced cold
hypersensitivity is TRPM8-dependent [4].
Similarly, neuropathic pain induced by the chronic constriction
injury (CCI) of the sciatic nerve induces symptoms of cold
hypersensitivity which have also been reported to be TRPM8-
dependent [4]. We confirmed these results, finding that by day six
post-injury, the acetone scores of wildtype mice were 4.160.1 (up
from 2.160.1 at baseline), which remained constant over the
following two days (Figure 9C; n=4). TRPM8
-/- mice exhibited a
score of 1.660.3 by day six post-injury, which was not significantly
differentfromthebaseline valueof1.360.1anddidnot significantly
increase over the next two days (Figure 9C; n=4; ANOVA,
p.0.05). As with the inflammatory model, these data reaffirm the
role of TRPM8 in CCI-evoked cold hypersensitivity [4].
Next we tested whether PBMC could reduce cold hypersensi-
tivity in these two pain models. For CFA-induced inflammation,
when 10 mg/kg PBMC was injected on the peak response day
(day two post-injury), we observed a response score of 2.560.2
(n=8) one hour after drug administration, which was significantly
lower than the vehicle control group (Figure 9B; Student’s t-test,
**p,0.01). The effect of PBMC wore off within 24 hours, when
acetone responses scores increased to 3.060.1, values not
significantly different from the vehicle control group (2.760.4;
Student’s t-test, p.0.05). Similarly, in the CCI model, when
10 mg/kg PBMC was administered to injured wildtype mice on
day seven post-injury, the behavioral response scores dropped to
3.060.1 one hour after the injection, a significant decrease when
compared to vehicle-treated animals (Figure 9D; n=4; Student’s t-
test, p,0.01). As for CFA, this amelioration of cold hypersensi-
tivity was transient with animals returning to the sensitized state 24
hours later (Figure 9D). Thus PBMC is effective in diminishing
Figure 5. PBMC inhibits TRPM8 currents. A) Representative whole-
cell voltage clamp recording from a mTRPM8-expressing HEK293T cell.
Currents, at both positive and negative potentials were measured
during a voltage ramp from 280 mV to +80 mV (1 V/s) and evoked
with 500 mM menthol (in the absence of extracellular calcium, with
10 mM EGTA in the pipette), followed by the addition of 0.25 nM then
2.5 nM PBMC for five minutes per concentration. Menthol was present
in the perfusate for the duration of the drug application (green bars)
and a perfusion artifact was inserted to demarcate the solution change.
B) Current-voltage relationships at the time points indicated in A. C)
Normalized currents plotted against a range of PBMC concentrations.
Reduction of TRPM8 currents by PBMC was dose-dependent at +80 mV
(squares) and 280 mV (circles). The calculated IC50 values were 0.6 nM
and 0.4 nM at positive and negative voltages, respectively (n=6–8 cells
per data point).
doi:10.1371/journal.pone.0025894.g005
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the indicated voltage step protocol. Traces show activity before and after application of 1 mM menthol and after application of 0.5 nM PBMC while
still in the presence of 1 mM menthol. B) Steady-state activation curves under basal, menthol, and menthol + PBMC conditions. The normalized
conductance (G/Gmax) was plotted against voltage and the addition of PBMC resulted in a reduction of the normalized conductance. Lines represent
Boltzmann functions fitted to the data (n=6–8 cells). C) Average voltages (mV) of half-maximal normalized conductance (V1/2) obtained from the
Boltzmann functions in B. The addition of PBMC with menthol shifted the V1/2 from 79.1621.1 mV to 171.2616.0 mV (Student’s t-test, **p,0.01),
towards the baseline value of 218.2618.2 mV.
doi:10.1371/journal.pone.0025894.g006
Figure 7. PBMC affects thermoregulation in a dose-dependent manner. A) Injection of 10 mg/kg icilin resulted in an average increase in
core body temperature of 1.6uC as measured by thermal telemetry. This hyperthermic response to icilin was not present in TRPM8
-/- animals, which
only exhibited a mild (,0.5uC) and transient (,30 minutes) increase, similar to that observed with vehicle (C). B) Injection of 1 mg/kg capsaicin
resulted in a robust hypothermic response (,4uC drop) in wildtype and TRPM8
-/- animals. C) Injection of vehicle (20% DMSO/80% saline (DS)) resulted
in no change in core body temperature in either genotype beyond a small spike in body temperature within 30 minutes of injection. D)
Intraperitoneal injection of warmed 10% Solutol/20% PEG-200/saline (SPS) vehicle resulted in no changes in core body temperature besides the
injection spike in either genotype. E) Injection of warmed 10 mg/kg PBMC resulted in a subtle hypothermic effect (,1uC drop) in wildtype mice
which resolved within three hours of injection, whereas TRPM8
-/- mice remained unaffected. F) Injection of warmed 20 mg/kg PBMC resulted in a
profound hypothermic response (.6uC drop within 45 minutes) in wildtype animals, which did not occur in TRPM8
-/- mice. Arrows indicate injection
time. Some error bars were omitted for clarity and all data are from 4–8 animals. Bars denote data that was statistically different (* p,0.05) between
wildtype and TRPM8
-/- mice.
doi:10.1371/journal.pone.0025894.g007
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inflammatory and neuropathic pain.
Finally, we tested the effect of PBMC on a systemic neuropathic
injury model. The platinum-based chemotherapeutic drug oxali-
platin is known to induce significant cold hypersensitivity which has
been attributed to TRPM8 [9,39,40]. Animals injected with
oxaliplatin developed a heightened response to acetone application
that increased from 2.360.2 at baseline to 3.360.1 by day three
post-injection and remained constant through day seven post-injury
(Figure 9E; n=8). This increase was absent in TRPM8
-/- mice
injected with oxaliplatin (1.160.2 at baseline; 1.560.2 by day three
post-injury; n=8; ANOVA, p.0.05), thus confirming that the
channel is required for oxaliplatin-induced cold hypersensitivity.
However, unlike the CFA and CCI models, 10 mg/kg PBMC did
not significantly attenuate cold hypersensitivity when administered
on day three post–injection, with scores only decreasing to 3.060.1
as compared to 3.360.1 for vehicle-treated animals (Figure 9F;
n=8 eachtreatment; Student’s t-test, p=0.08). Therefore,at a dose
of 10 mg/kg, PBMC is effective at attenuating symptoms of cold
hypersensitivity in the CFA model of inflammatory pain and the
CCI model of neuropathic pain, but not in the systemic oxaliplatin-
induced neuropathic pain model. We did not test higher doses due
to the significant effects on thermoregulation (Figure 7F) which
would likely complicate interpretation of these results.
Discussion
Here we show that PBMC is a robust and selective TRPM8
antagonist. In vitro, PBMC is the most potent TRPM8 antagonist
reported to date and inhibits channel activation to both chemical
and thermal stimuli. Using calcium microfluorimetry and whole-
cell electrophysiology, we found that PBMC reduced TRPM8
activity in a dose-dependent manner. Indeed, we observed an IC50
concentration of less than 1 nM, a dosage approximately 100-fold
lower than the most potent TRPM8 antagonist reported to date,
CTPC [16,17]. Thus, the two-orders-of-magnitude higher affinity
of PBMC makes this compound a more amenable reagent in the
study of TRPM8 channel function.
Importantly, and unlike other TRPM8 antagonists, we did not
observe any cross reactivity with either TRPV1 or TRPA1,
suggesting that PBMC is selective for TRPM8. However, these
observations are not all inclusive of other cellular mechanisms, but
application of PBMC to cultured TG neurons did not lead to any
noticeable changes in cellular excitability, suggesting that PBMC
does not have any appreciable off-target effects at the level of
cultured sensory neurons. We found that PBMC exerts its
antagonistic effect on TRPM8 by shifting the voltage-dependence
of TRPM8 gating. This particular result, consistent with previous
reports from our lab and others, suggests that many (if not all
types) of functional regulation of TRPM8—whether by agonist,
antagonist, or adaptive mechanisms—involves changes in voltage-
dependent gating [32,34,35,41].
Emerging evidence suggests that TRPM8 plays a role in
thermoregulation, both with the stimulation of skin afferents with
chemical agonists [36,42,43] or cooling [11]. Here, we have
confirmed that icilin, a chemical TRPM8 agonist more potent
than menthol [16,37] can also induce an increase in body
temperature [36], an effect that is TRPM8-dependent [5,6],
despite reports that icilin can also activate TRPA1 in vitro [44].
Even though TRPM8
-/- mice do not respond to icilin, these
animals retain the ability to mount a chemically-induced
thermoregulatory response as we observed an identical effect in
both wildtype and TRPM8
-/- mice in response to the TRPV1-
agonist capsaicin. Therefore it appears that TRPM8-expressing
afferents have the ability to affect thermoregulatory responses to
both chemical and thermal stimuli, although the exact neurolog-
ical mechanism remains to be explored.
Due to this evidence and recent reports of TRPV1 antagonists
having undesired thermoregulatory effects [12,13], we were
concerned that a TRPM8 antagonist would also affect thermo-
regulation. Indeed, when we administered PBMC at a dose of
20 mg/kg, we observed a profound hypothermic effect, with one
mouse reaching body temperatures below the temperature range
of the telemeter (,30uC), a temperature classified as deep
hypothermia in humans [45]. The pharmacokinetics of PBMC
are as yet unknown, yet the hypothermic effect observed here
lasted around four hours on average, and in thermoregulatory and
behavioral experiments the effects were gone by less than one day
after administration. Interestingly, halving the dose (10 mg/kg)
almost completely abolished the hypothermic response, with core
body temperatures dropping less than one degree—a surprising
Figure 8. PBMC reduces acute cold-evoked behavioral re-
sponses. A) In the acetone evaporative cooling assay, wildtype mice
exhibited an average response score of 2.260.1, while treatment with
10 mg/kg PBMC reduced this score to 1.860.1 (Student’s t-test,
**p,0.01 vs. baseline) and treatment with 20 mg/kg PBMC reduced it
further to 1.460.1 (Student’s t-test, ***p,0.001 vs. baseline). B) Every
mouse given 10 mg/kg PBMC showed a decrease in acetone response
scores ranging from 0.1 (orange stars, violet hexagons) to 1.1 (black
triangle).
doi:10.1371/journal.pone.0025894.g008
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this drop in core temperature was significantly different than
vehicle injected control or TRPM8
-/- mice, it was not significant
when compared to normal circadian changes in body temperature
we observed in these mice. Thus, we suggest that the slight change
in core temperature observed at the 10 mg/kg dose did not
participate in the ability of PBMC to block acute cold sensation, as
well as reduce injury-induced cold hypersensitivity.
It has been shown extensively that TRPM8 is required for cold
sensation, particularly in the evaporative cooling assay [3,4,5,6].
When a small volume of acetone is applied to the hindpaw of a
mouse, it quickly evaporates and cools the skin down to
temperatures as low 14–18uC [4], which is near the loose
boundary of the transition from innocuous cool to cold pain
[46]. With 10 mg/kg PBMC, we observed a partial reduction in
the normal acetone response score, demonstrating that by blocking
TRPM8, this compound can alter cold thermosensation. These
responses were further reduced with the highest concentration
tested, 20 mg/kg, although the interpretation of these effects are
complicated by the dramatic hypothermia produced at this
Figure 9. PBMC reduces cold hypersensitivity in CFA and CCI but not oxaliplatin pain models. A) In the CFA model of inflammatory pain,
wildtype animals showed an increase in behavioral response scores which peaked at 3.560.3 at two days post-injury, whereas scores for TRPM8
-/-
mice did not change significantly from the baseline (BL) of 1.960.4 (ANOVA, p.0.05). B) PBMC (10 mg/kg) administered to wildtype mice on day two
post-CFA-injection resulted in a significant decrease in scores to 2.560.2 (Student’s t-test, **p,0.01). The effect of the drug was gone within 24 hours,
with PBMC-treated animals average score of 3.060.1, which was not significantly different from the 2.760.4 score of vehicle-treated animals
(Student’s t-test, p.0.05). C) In the CCI model of neuropathic pain, wildtype animals exhibited a response score of 4.160.1 by day six post-injury,
which remained constant through day eight. TRPM8
-/- mice exhibited no significant increase in responses over baseline, with scores reaching 1.760.3
by day six post-injury (ANOVA, p.0.05). D) Treatment of CCI-wildtype animals with 10 mg/kg PBMC resulted in a decrease in score on day seven
post-injury to 3.060.1, which was significantly lower than 4.060.2 in vehicle-treated animals (Student’s t-test, **p,0.01). Scores of PBMC-injected
animals increased to 4.160.2 by 24 hours post-treatment, which was the same score for vehicle-treated animals. E) In the oxaliplatin-induced model
of neuropathic pain, wildtype animals showed a peak score of 3.360.1 by day three, which remained constant through day seven at 3.260.2.
TRPM8
-/- animals showed no significant changes in score over the seven day period (ANOVA, p.0.05). F) Wildtype animals treated on day three post-
injury with 10 mg/kg showed a slight reduction (3.060.1) in acetone score as compared to vehicle-treated animals (3.360.1) although this decrease
was not statistically significant (Student’s t-test, p=0.08).
doi:10.1371/journal.pone.0025894.g009
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not drop to the level of TRPM8
-/- mice (Figure 9), indicating
partial blockade of the channel at this dose. Interestingly, we
observed individual differences in the amplitude of the score
reduction with 10 mg/kg PBMC under normal conditions, which
may suggest that, at this low dose, individual variations in
physiology may affect drug action. However, due to the
thermoregulatory effects described above, we were limited in the
amount of drug we could administer to the mice without
potentially confounding thermosensory responses.
TRPM8 has also been implicated in the painful cold
hypersensitivity that is a distressing symptom of inflammatory
and neuropathic conditions, as well as platinum-based chemo-
therapy drugs [4,9]. It would therefore be greatly beneficial to
both chronic pain and chemotherapy patients to have a drug
which could control such symptoms. Thus we tested whether
PBMC could reduce the behavioral responses to evaporative
cooling in models of inflammatory and neuropathic pain. In the
CFA model of inflammatory pain and the CCI model of
neuropathic pain, we saw a reduction in the response scores of
mice treated with 10 mg/kg PBMC. Interestingly, both of these
reduced scores remained higher than those seen at baseline or with
TRPM8
-/- mice, again suggesting that at this dose PBMC only
partially blocked TRPM8 function in vivo. However, given that the
aim of a good symptom-controlling drug would be to reduce the
hypersensitivity to cold without abolishing normal thermosensa-
tion (e.g. numbness), this may not be a completely undesirable
effect.
In contrast, when we examined oxaliplatin-treated animals
given PBMC, we did not see a statistically significant reduction in
response scores. It is puzzling that PBMC would be effective
against one model of neuropathic pain (CCI) but not another.
There are two probable explanations for this observation: First, it
is possible that other mechanisms may also be involved in cold
hypersensitivity in oxaliplatin-induced neuropathy and PBMC is
ineffective against these mechanisms [47], although our and
others’ recent evidence suggests that TRPM8 plays a pivotal role
in this pathology [9,39]. Alternatively, it may be that the partial
inhibition of TRPM8 we observe with PBMC prevents this
compound from being effective in reducing the response scores in
this pain model. Again, as we were constrained by the
hypothermic side effect of a higher dose, we were unable to test
if higher doses could provide some level of analgesia in oxaliplatin-
induced cold hypersensitivity. Reformulation of the drug, if
possible, may yield a compound that specifically targets sensory
afferents without having the strong thermoregulatory effect
observed here. Such a drug may bring much-needed relief to
both chronic pain and chemotherapy patients experiencing
symptoms of cold hypersensitivity. Nonetheless, our results show
that PBMC is a potent and selective inhibitor of TRPM8, and that
inhibition of this channel alters cold sensation, thermoregulation,
and provides a modest level of relief in rodent models of injury-
induced cold pain.
Materials and Methods
Animals
All mice used in this study were adults aged at least eight weeks.
Wildtype and TRPM8-knockout mice [3,6] were on the same
C57Bl/6 genetic background, and all animals were provided
standard mouse chow and water ad libitum. All procedures and
tests were approved by the University of Southern California
Institutional Animal Care and Use Committee (Protocol number:
10674; Approval date: 12/08/2010) and conducted in accordance
with the recommendations of the International Association for the
Study of Pain and the NIH Guide for the Care and Use of Laboratory
Animals.
Heterologous expression
Complementary DNA (cDNA) of mouse TRPM8 (gifts from A.
Patapoutian), rat TRPV1, and rat TRPA1 (gifts from D. Julius)
clones were transfected into the human embryonic kidney cell line
293-T (HEK293T) using TransIT-LT1 reagent (Mirus, Madison,
WI) following the manufacturer’s instructions. Cells were main-
tained in a 37uC incubator in 5% CO2 in DMEM containing 10%
fetal bovine serum and 1% penicillin-streptomycin.
Neuronal Cell Culture
Trigeminal ganglia were dissected from newborn mice and
dissociated with 0.25% collagenase P (Roche Applied Science,
Indianapolis, IN) in a solution of 50% DMEM (Dulbecco’s
Modification of Eagle’s Medium with 4.5 g/L gluscose, L-
glutamine and sodium pyruvate, Mediatech, Inc., Manassas,
VA), and 50% F-12 (HAM F-12 Nutrient Mixture with L-
glutamine, Invitrogen Corporation, Carlsbad, CA) for 30 minutes.
The ganglia were then pelletted and resuspended in 0.05% trypsin
at 37uC for 2 minutes, and triturated gently with a fire-polished
Pasteur pipette in culture medium (DMEM/F-12 with 10% FBS
and penicillin-streptomycin). Cells were then resuspended in
culture medium with nerve growth factor 7S (Invitrogen
Corporation, Carlsbad, CA) (100 ng/ml) and plated onto
coverslips coated with Matrigel (BD Biosciences, Inc., San Jose,
CA) (20 ul/ml). Cultures were examined 16–20 hours after
plating.
Calcium microfluorimetry
Intracellular Ca
2+ was determined with the cell-permeable form
of Fura-2 (Invitrogen, Carlsbad, CA) as described [1,32] and
pseudo-colored ratiometric images were captured on an Olympus
IX70 fluorescent microscope with Sutter Lambda LS light source,
Roper CoolSnap ES camera, and the MetaImaging Software
suite. Solutions were gravity-fed through tubes connected to an 8-
channel perfusion valve solution controller (Warner Instruments,
Hamden, CT). Temperature readings were captured by a CL-100
Temperature Controller (Warner Instruments, Hamden, CT)
through a PowerLab 8/30 digital-to-analog converter (ADInstru-
ments, Colorado Springs, CO). Data are represented as the mean
6 the standard error and statistical significance was determined
using a Student’s t-test.
Mammalian cell electrophysiology
Voltage clamp recordings were performed as described [32].
Standard bath solution for whole-cell recordings contained (in
mM): 136 NaCl, 5.4 KCl, 1 MgCl2, 1.8 CaCl2, 10 HEPES, 10
glucose, and 0.33 NaH2PO4 and adjusted to pH 7.4 with NaOH.
Pipette solution contained (in mM): 140 CsCl, 10 EGTA, 2
MgATP, and 10 HEPES and adjusted to pH 7.4 with CsOH.
Nominally Ca
2+-free bath solutions contained (in mM): 136 NaCl,
5.4 KCl, 1 MgCl2, 10 HEPES, 10 glucose, and 0.33 NaH2PO4
and adjusted to pH 7.4 with NaOH. Recordings were performed
using an Axopatch 200B amplifier and Digidata 1320 data
acquisition board with pCLAMP 9.2 software (all Molecular
Devices, Inc., Sunnyvale, CA). Solutions were gravity-fed through
tubes connected to an 8-channel perfusion valve solution
controller (Warner Instruments, Hamden, CT). Rapid solution
exchange was performed as previously described [32]. Briefly,
rapid bath solution exchange was achieved by placing the cell in a
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a linear array of microperfusion pipes under computer control
(Warner Instruments, Hamden, CT). All drugs used in our
experiments were stored and handled following the manufacturer’s
instructions.
Voltage-dependent gating data analysis
Data analysis was performed using Origin 8.1 (OriginLab
Corporation, Northampton, MA). Steady-state activation curves
were determined using previously described methods [32,34,35].
Briefly, to estimate maximal TRPM8 activity at a given voltage, we
used a saturating dose of 1 mM menthol [1] at room temperature
(23uC)toactivateTRPM8andmeasuredcurrentsatthe end ofeach
voltage step. We then calculated the conductance, G, at each data
point, using the relation g=I ss/V, where Iss is the steady-state
current at the end of a voltage step, and V is the voltage difference
across the cell membrane. Because the conductance appears to
saturate and reach a maximum, we calculated G/Gmax for each
value, thus normalizing data so that comparisons could be made
between cells. For simplicity, we assume for our calculations a two-
state model of channel gating[34]. However, it should be notedthat
other reports have identified several additional channel states
beyond the two originally described [32,34,35,41,48]. Therefore we
fit the G/Gmax values with steady-state activation curves using a
Boltzmann function of the form:
G=Gmax~
1
1zexp({
zapp
kBT (V{V1=2))
where zapp is the experimentally determined gating charge, kB is the
Boltzmann constant (1.38610–23 J K
21) and T is the absolute
temperature. The half-maximal conductance (V1/2) is estimated
from these steady-state activation curves for each cell. Data are
represented as the mean 6 the standard error and statistical
significance was determined using a Student’s t-test.
Pharmacological data analysis
Data analysis was performed using Origin 8.1 (OriginLab
Corporation, Northampton, MA). Dose-response curves were fit
with a Hill equation of the form
Y~Vmax
xn
knzxn
where Vmax is the maximum velocity of the reaction, k is the
substrate constant, and n is the Hill coefficient. Data are
represented as the mean 6 the standard error.
Thermal telemeter implantation and core temperature
monitoring
Mice were implanted with G2 e-mitters (Mini Mitter, Bend, OR)
according to the manufacturer’s instructions. Briefly, under sterile
conditions, mice were anesthetized with 4% isoflurane and
maintained with 2% isoflurane in oxygen. The ventral surface
was shaved and sterilized and a 2 cm incision was made in the skin,
and a 1.5 cm incision made in the abdominal wall. A chemically-
sterilized e-mitter was gently nestled amongst the small intestines
with care not to compress any vital organs and anchored to the
abdominal wall with 5–0 Vicryl sutures. The peritoneum was
sutured, and the overlying skin closed with tissue adhesive. The
animals were allowed to recover for 30 minutes in a warmed
recovery cage before returning to their home cages. The animals
were given 0.03 mg/kg buprenorphine 15 minutes prior to surgery
and again every 12 hours post-surgery for a total of 48 hours. The
animals’ health and recovery were monitored by USC Department
of Animal Resources staff. Animals were allowed to recover from
surgery for at least one week to ensure the absence of infection and
fever. On the day of experiments, animals were acclimated to the
experiment room at least one hour prior to the commencement of
temperature monitoring. The VitalView software package (Mini
Mitter, Bend, OR) was used for automated temperature monitor-
ing, with the temperature recording limits set to 40–30uC and the
monitoring period set to every five minutes. Animals were provided
standard mouse chow and water ad libitum during the testing period
and allowed at least two days recovery between experiments.
Baseline temperatures were calculated by averaging the tempera-
ture readings over the thirty minutes immediately prior to injection.
The change in core temperature (DT) was calculated by subtracting
the baseline temperature from the observed temperature. Care was
taken to perform experiments at the same time of day so as to
minimize circadian influences on temperature readings. Data are
representedasthe mean6standarderrorandstatisticalsignificance
was determined using a Student’s t-test.
Chemicals
Icilin (Tocris Bioscience, Ellisville, Missouri) was dissolved to a
concentration of 24 mg/ml in DMSO and then diluted to 1 mg/ml
in 20% DMSO/80% saline (DS vehicle) and administered at
10 mg/kg. A stock solution of 10 mg/ml capsaicin in ethanol was
dilutedto 0.1 mg/ml inthe same vehicleand administered at a dose
of 1 mg/kg. The vehicle was administered at the same volume
(10 ml/kg) as both icilin and capsaicin. These solutions were
administered subcutaneously to the dorsal surface of the animal.
PBMCwasaprovidedasagenerousgiftfromPfizerInc.(Sandwich,
Kent, U.K.) and dissolved in DMSO for cellular assays. For in vivo
injections, the drug was suspended in a vehicle solution of 10%
Solutol (Sigma-Aldrich, St. Louis, MO), 20% PEG-200 in normal
saline (SPS vehicle) to a concentration of 2.5 mg/ml. PBMC and
SPS vehicle solutions were administered either subcutaneously or
intraperitoneally at doses of 2, 10, or 20 mg/kg, as outlined in the
text. For behavioral testing, the animals were allowed to settle for
one hour following PBMC injections.
Evaporative cooling assay
The evaporative cooling assay was performed as follows: Mice
were acclimated for fifteen minutes in an elevated, four-place
chamber with a mesh floor. A syringe with a piece of rubber tubing
attachedtotheendwasfilledwithacetoneandtheplungerdepressed
so that a small drop of acetone formed at the top of the tubing. The
syringe was raised to the mouse’s hindpaw from below, depositing
the acetone drop onthe paw. Micewere tested fourat a time with an
inter-stimulation period of four minutes per mouse, alternating paws
between stimulations. Responses were video recorded for later
quantification by an observer blind to the experimental conditions.
Behaviors were scored according to the magnitude of the response
along the following scale: 0-no response; 1-brief lift, sniff, flick, or
startle; 2-jumping, paw shaking; 3-multiple lifts, paw lick; 4-
prolonged paw lifting, licking, shaking, or jumping; 5-paw guarding.
The scale was designed so that the extreme values (0 and 5) occurred
only rarely. Data are represented as the mean 6 standard error.
Statistical significance was assessed using either the paired or
unpaired Student’s t-test or one-way ANOVA, as appropriate.
Pain models
Inflammatory injury was induced by unilateral intraplantar
injection of 20 ml of complete Freund’s adjuvant (CFA). The
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induced as follows: Under sterile conditions, mice were anesthe-
tized with 5% isoflurane and anesthesia maintained with 3%
isoflurane in oxygen. The animal was positioned so that the right
flank was accessible and the leg supported with a roll of gauze. The
flank surface was closely shaved and sterilized and a 2 cm incision
was made in the skin. The muscle was gently pried apart until the
sciatic nerve was revealed. Three 6–0 chromic gut sutures were
loosely tied around the nerve about 1 mm apart. The muscle was
closed, and the skin was closed with tissue adhesive. The animals
were allowed to recover for 30 minutes in a warmed recovery cage
before returning to their home cages. The animals’ health and
recovery were monitored by USC Department of Animal
Resources staff. Systemic neuropathic injury was induced by
intraperitoneal injections of 3 mg/kg oxaliplatin (Sigma-Aldrich)
dissolved in a 5% glucose/saline solution.
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